strontium ranelate (Protelos)

Tradename: Protelos (not yet FDA approved 2004) Indications: 1) osteoporosis 2) strontium-89 used as radiopharmaceutical in the treatment of pain from bone metastases Dosage: 682 mg of elemental strontium/day Adverse effects: -> may result in defective bone growth Mechanism of action: 1) Sr+2 can replace Ca⁺² in bone tissue 2) seems to decrease risk of osteoporosis in postmenopausal women

References

Prescriber's Letter 11(3):17 2004 Detail-Document#: 200314 (subscription needed) http://www.prescribersletter.com